Caso clínico
Rivaroxabán en síndrome antifosfolipídico tras fracaso con acenocumarol: a propósito de 2 casos
After failure with acenocoumarol, rivaroxaban in antiphospholipid syndrome: A report of 2 cases
Javier José Mateos Rodrígueza,
, David Bellidob, David Castroa, José Portillo Sánchezb, Raúl Vanegasc, Alicia Núñez Garcíad
Autor para correspondencia
a Servicio de Reumatología, Hospital General Universitario de Ciudad Real, Ciudad Real, España
b Servicio de Medicina Interna, Hospital General Universitario de Ciudad Real, Ciudad Real, España
c Servicio de Hematología, Hospital General Universitario de Ciudad Real, Ciudad Real, España
d Medicina de Familia, Ciudad Real, España
Leído
15710
Vecesse ha leído el artículo
3124
Total PDF
12586
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 6 | 6 | 4 | 10 |
| 2025 5 | 284 | 41 | 325 |
| 2025 4 | 287 | 51 | 338 |
| 2025 3 | 253 | 37 | 290 |
| 2025 2 | 254 | 40 | 294 |
| 2025 1 | 216 | 45 | 261 |
| 2024 12 | 201 | 47 | 248 |
| 2024 11 | 249 | 65 | 314 |
| 2024 10 | 251 | 38 | 289 |
| 2024 9 | 206 | 29 | 235 |
| 2024 8 | 239 | 37 | 276 |
| 2024 7 | 256 | 33 | 289 |
| 2024 6 | 249 | 34 | 283 |
| 2024 5 | 252 | 40 | 292 |
| 2024 4 | 288 | 46 | 334 |
| 2024 3 | 229 | 42 | 271 |
| 2024 2 | 185 | 34 | 219 |
| 2024 1 | 195 | 22 | 217 |
| 2023 12 | 184 | 17 | 201 |
| 2023 11 | 228 | 37 | 265 |
| 2023 10 | 231 | 37 | 268 |
| 2023 9 | 305 | 42 | 347 |
| 2023 8 | 220 | 21 | 241 |
| 2023 7 | 258 | 32 | 290 |
| 2023 6 | 244 | 34 | 278 |
| 2023 5 | 302 | 29 | 331 |
| 2023 4 | 173 | 23 | 196 |
| 2023 3 | 237 | 48 | 285 |
| 2023 2 | 196 | 26 | 222 |
| 2022 1 | 167 | 19 | 186 |
| 2022 12 | 154 | 45 | 199 |
| 2022 11 | 210 | 50 | 260 |
| 2022 10 | 190 | 62 | 252 |
| 2022 9 | 178 | 36 | 214 |
| 2022 8 | 215 | 65 | 280 |
| 2022 7 | 194 | 45 | 239 |
| 2022 6 | 142 | 63 | 205 |
| 2022 5 | 168 | 76 | 244 |
| 2022 4 | 162 | 56 | 218 |
| 2022 3 | 216 | 56 | 272 |
| 2022 2 | 171 | 40 | 211 |
| 2021 1 | 153 | 50 | 203 |
| 2021 12 | 156 | 49 | 205 |
| 2021 11 | 141 | 49 | 190 |
| 2021 10 | 180 | 63 | 243 |
| 2021 9 | 113 | 51 | 164 |
| 2021 8 | 101 | 55 | 156 |
| 2021 7 | 111 | 70 | 181 |
| 2021 6 | 134 | 78 | 212 |
| 2021 5 | 148 | 52 | 200 |
| 2021 4 | 310 | 87 | 397 |
| 2021 3 | 193 | 51 | 244 |
| 2021 2 | 105 | 29 | 134 |
| 2020 1 | 105 | 38 | 143 |
| 2020 12 | 108 | 29 | 137 |
| 2020 11 | 107 | 23 | 130 |
| 2020 10 | 134 | 23 | 157 |
| 2020 9 | 99 | 35 | 134 |
| 2020 8 | 100 | 28 | 128 |
| 2020 7 | 97 | 19 | 116 |
| 2020 6 | 102 | 22 | 124 |
| 2020 5 | 145 | 24 | 169 |
| 2020 4 | 108 | 23 | 131 |
| 2020 3 | 99 | 30 | 129 |
| 2020 2 | 1 | 2 | 3 |
| 2019 12 | 2 | 2 | 4 |
| 2019 11 | 2 | 2 | 4 |
| 2019 10 | 3 | 0 | 3 |
| 2019 5 | 156 | 41 | 197 |
| 2019 4 | 105 | 32 | 137 |
| 2019 3 | 125 | 34 | 159 |
| 2019 2 | 88 | 35 | 123 |
| 2019 1 | 99 | 30 | 129 |
| 2018 12 | 91 | 41 | 132 |
| 2018 11 | 9 | 15 | 24 |
| 2018 10 | 9 | 13 | 22 |
| 2018 9 | 2 | 10 | 12 |
| 2018 8 | 0 | 8 | 8 |
| 2018 7 | 0 | 5 | 5 |
| 2018 5 | 0 | 3 | 3 |
| 2018 4 | 0 | 19 | 19 |
| 2018 3 | 0 | 23 | 23 |
| 2018 2 | 0 | 16 | 16 |
| 2018 1 | 0 | 13 | 13 |
| 2017 12 | 0 | 19 | 19 |
| 2017 11 | 0 | 13 | 13 |
| 2017 10 | 0 | 14 | 14 |
| 2017 9 | 0 | 24 | 24 |
| 2017 8 | 0 | 13 | 13 |
| 2017 7 | 0 | 21 | 21 |
| 2017 6 | 0 | 37 | 37 |
| 2017 5 | 0 | 17 | 17 |
Mostrar todo
